Eunice L. Kwak

TL;DR: PF-02341066 (PF) is a small molecule oral inhibitor of the c-Met/HGFR and ALK receptor tyrosine kinases that has not previously been tested in humans as discussed by the authors.

TL;DR: The phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma and a single‐arm, phase 1/2 study of everolimus in patients with advanced HCC is performed.

TL;DR: The combination of neratinib and temsirolimus was tolerable and demonstrated antitumor activity in multiple tumor types, warranting further evaluation.

TL;DR: The presence of activating mutations within EGFR in both esophageal and pancreatic adenocarcinomas defines a previously unrecognized subset of gastrointestinal tumors in which EGFR signaling may play an important biological role.

TL;DR: The combination of capecitabine and erlotinib is active in patients with gemcitABine-refractory pancreatic cancer and may represent an acceptable treatment option in patients who experience treatment failure with standard first-line therapy with gem citabine or for whom gemcit abine may not be an appropriate first- line treatment option.